UNI-MB - logo
UMNIK - logo
 
E-viri
Celotno besedilo
Recenzirano
  • Reduced MMP-2 activity cont...
    Van Linthout, Sophie; Seeland, Ute; Riad, Alexander; Eckhardt, Oleg; Hohl, Mathias; Dhayat, Nasser; Richter, Utz; Fischer, Jens W.; Böhm, Michael; Pauschinger, Matthias; Schultheiss, Heinz-Peter; Tschöpe, Carsten

    Basic research in cardiology, 06/2008, Letnik: 103, Številka: 4
    Journal Article

    Objective To evaluate the regulation of matrix metalloproteinase (MMP)-2 in diabetic cardiomyopathy. Methods Left ventricle (LV) function was determined by a micro-tip catheter in streptozotocin (STZ)-induced diabetic rats, 2 or 6 weeks (w) after STZ-application. LV total collagen, collagen type I and III content were immunohistologically analyzed and quantified by digital image analysis. LV collagen type I, III and MMP-2 mRNA expression was quantified by real-time RT-PCR. LV pro- and active MMP-2 levels were analyzed by zymography; Smad 7, membrane type (MT)1-MMP and tissue inhibitor metalloproteinase (TIMP)-2 protein levels by Western Blot. Results STZ-induced diabetes was associated with a time-dependent impairment of LV diastolic and systolic function. This was paralleled by a time-dependent increase in LV total collagen content, despite reduced LV collagen type I and III mRNA levels, indicating a role of post-transcriptional/post-translational changes of extracellular matrix regulation. Six weeks (w) after STZ-injection, MMP-2 mRNA expression and pro-MMP-2 levels were 2.7-fold ( P < 0.005) and 1.3-fold ( P < 0.05) reduced versus controls, respectively, whereas active MMP-2 was decreased to undetectable levels 6 w post-STZ. Concomitantly, Smad 7 and TIMP-2 protein levels were 1.3-fold ( P < 0.05) and 10-fold ( P < 0.005) increased in diabetics versus controls, respectively, whereas the 45 kDa form of MT1-MMP was undetectable in diabetics. Conclusion Under STZ-diabetic conditions, cardiac fibrosis is associated with a dysregulation in extracellular matrix degradation. This condition is featured by reduced MMP-2 activity, concomitant with increased Smad 7 and TIMP-2 and decreased MT1-MMP protein expression, which differs from mechanisms involved in dilated and ischemic heart disease.